Cancer drugmakers gain after Roche discloses positive data from drug study

Arcus Biosciences

23/08/2023 15:27

(Updates)
    ** U.S.-listed shares of cancer drugmakers rise after
Switzerland-listed Roche  ROG.S  reports positive data from a
new immunotherapy study for lung cancer patients
    ** The study used a new experimental class of drugs known as
 anti-TIGIT
    ** Rival drugmaker Merck & Co  MRK.N  up 4% at $111.6,
Gilead Sciences  GILD.O  rises 1.9% to $77.8, as they are also
evaluating the anti-TIGIT drugs for various oncology diseases
    ** Among other anti-TIGIT drug developers, iTeos
Therapeutics  ITOS.O  soars 47.1% to $17.27, Arcus Biosciences
 RCUS.N  jumps 31.4% to $24.7
        ** U.S. shares of Compugen  CGEN.O   CGEN.TA  climbs
17.5% at $1.2, and Mereo Biopharma  MERO.O   MAH0y.F   up 4.4%
to $1.3
    ** Roche said interim results regarding overall survival
were not mature at the time of the second interim analysis,
adding the study would continue until a final analysis
    ** Analysts say while the data is not mature, it still
raises hope regarding the success of the final analysis
        
  
    

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))